Particle accelerators

Best Cyclotron Systems Announces Successful Completion of Initial Factory Acceptance Test for B6–15 MeV Proton Cyclotron

Retrieved on: 
Wednesday, July 7, 2021
Research, Medical devices, Hospitals, Other Health, Biotechnology, General Health, Health, Science, Oncology, Other Science, Particle accelerators, Accelerator physics, Physics, Physical sciences, Cyclotron, Nuclear medicine, Academic disciplines

On June 30, 2021, teams from Best Cyclotrons Systems (BCS in Vancouver, Canada) and sister-company Best Theratronics Ltd. (BTL in Ottawa, Canada) of TeamBest Global Companies (TBG), successfully completed the initial Factory Acceptance Test (FAT) for their novel Best 615 MeV Proton Cyclotron for a National Lab.

Key Points: 
  • On June 30, 2021, teams from Best Cyclotrons Systems (BCS in Vancouver, Canada) and sister-company Best Theratronics Ltd. (BTL in Ottawa, Canada) of TeamBest Global Companies (TBG), successfully completed the initial Factory Acceptance Test (FAT) for their novel Best 615 MeV Proton Cyclotron for a National Lab.
  • Krishnan Suthanthiran, President & Founder of TBG Companies said, "Today is a fantastic day, as the BCS-Vancouver and BTL-Ottawa teams worked flawlessly together in accomplishing the successful Factory Acceptance Test for the newest B6-15p Cyclotron, a very high current, variable energy system.
  • The New Best 615 MeV Variable Energy Cyclotron is a Shielded, Compact, High Current, Multi-Use Proton Cyclotron System, capable of producing a variety of medical isotopes for diagnosis and therapy, as well as generating neutron beams.
  • For more information about TeamBest Global Companies, Best Cyclotron Systems and Best Theratronics Ltd., please visit:

NorthStar Medical Radioisotopes Receives Electron Beam Accelerators for First-of-its-Kind Advanced Medical Radioisotope Production

Retrieved on: 
Tuesday, May 11, 2021
Oncology, Health, Medical devices, Radiology, Pharmaceutical, Cardiology, Biotechnology, Northstar, Particle accelerators

The Company has received two custom-built IBA Rhodotron\xc2\xaeTT 300-HE (High Energy) electron beam accelerators at its facility in Beloit, Wisconsin.

Key Points: 
  • The Company has received two custom-built IBA Rhodotron\xc2\xaeTT 300-HE (High Energy) electron beam accelerators at its facility in Beloit, Wisconsin.
  • The Company\xe2\x80\x99s Accelerator Production facility in Beloit will add significant Mo-99 capacity, enable flexible production scheduling and minimize customer supply risks.\n\xe2\x80\x9cDelivery of these electron beam accelerators to advance Mo-99 production marks a tremendous milestone event for NorthStar, nuclear medicine and the patients who rely on diagnostic imaging studies for their health,\xe2\x80\x9d said Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes.
  • \xe2\x80\x9cUsing electron beam accelerators is one of the most efficient methods of producing Mo-99, and like other NorthStar processes, it is non-uranium based and environmentally friendly.
  • Additionally, electron beam accelerators can be used to produce therapeutic radioisotopes such as actinium-225 and copper-67.

An Open Letter to Users of Cyclotrons (up to 20 MeV), PETNET, Nuclear Pharmacy & PET/CT for Their Radioisotope Needs

Retrieved on: 
Tuesday, April 27, 2021
Medical devices, Hospitals, Health, Radiology, Oncology, Nuclear medicine, Medicine, Physical sciences, Medicinal radiochemistry, Medical physics, Neuroimaging, Accelerator physics, Particle accelerators, Cyclotron, Positron emission tomography, Radioactive tracer, PET-CT

b"Best ABT, a company of TeamBest Global (TBG) Group, is planning to introduce a new cyclotron \xe2\x80\x94 the Best Sub-Compact Model 200 \xe2\x80\x94 which can fulfill a hospital\xe2\x80\x99s needs for PET imaging and other similar small cyclotrons.

Key Points: 
  • b"Best ABT, a company of TeamBest Global (TBG) Group, is planning to introduce a new cyclotron \xe2\x80\x94 the Best Sub-Compact Model 200 \xe2\x80\x94 which can fulfill a hospital\xe2\x80\x99s needs for PET imaging and other similar small cyclotrons.
  • The new cyclotron will have a push-button control and one or more chemistry boxes that can be placed near the PET/CT, eliminating the need to transport radioisotopes from the cyclotron operation to PET/CT locations.
  • The Best Model 200 is self-shielded, with an internal ion source.
  • This is the only such cyclotron in the world.

Asia Pacific Medical Cyclotron Market Forecast to 2027 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 24, 2021
Health, General Health, Particle accelerators, Accelerator physics, Cyclotron, Nuclear medicine, Trend

The "Asia Pacific Medical Cyclotron Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type; Capacity; End User, and Country" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Pacific Medical Cyclotron Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type; Capacity; End User, and Country" report has been added to ResearchAndMarkets.com's offering.
  • The report highlights trends prevailing in the Asia Pacific medical cyclotron market and the factors driving market along with those that act as hindrances.
  • Determine prospective investment areas based on a detailed trend analysis of the Asia Pacific medical cyclotron market over the next years.
  • Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Asia Pacific medical cyclotron market.

IONETIX Announces Targeted Alpha Therapy Manufacturing Center

Retrieved on: 
Tuesday, March 16, 2021
Physical sciences, Natural sciences, Physics, Nuclear medicine, Accelerator physics, Medical physics, Particle accelerators, Nuclear technology, Targeted alpha-particle therapy, Cyclotron, Lansing, Michigan, Radionuclide

ft. facility in Lansing, MI for its new Targeted Alpha Radionuclide Manufacturing Center.

Key Points: 
  • ft. facility in Lansing, MI for its new Targeted Alpha Radionuclide Manufacturing Center.
  • IONETIX is currently developing a 30MeV cyclotron utilizing the same proprietary cyclotron technology platform employed in their ION 12SC cyclotron.
  • Targeted Alpha Therapy has the potential to be a life-changing and life-saving cancer treatment option to which IONETIX can make great contributions.
  • The new Targeted Alpha Radionuclide Manufacturing Center is slated to open in early 2022 and will create over 30 new skilled jobs in the Lansing area once fully operational.

Worldwide Medical Cyclotron Industry to 2027 - Availability of Technologically Advanced Diagnostic Devices Presents Opportunities

Retrieved on: 
Tuesday, March 16, 2021
Particle accelerators, Companies, Accelerator physics, Industry economics), Advanced Cyclotron Systems, Manufacturing, Cyclotron, Varian Medical Systems, Siemens

According to this report the global medical cyclotron market is expected to reach US$ 238.21 million by 2027 from US$ 180.00 million in 2019.

Key Points: 
  • According to this report the global medical cyclotron market is expected to reach US$ 238.21 million by 2027 from US$ 180.00 million in 2019.
  • Based on capacity, the medical cyclotron market is segmented into 10-12 MeV, 16-18 MeV, 19-24 MeV, and 24 MeV and above.
  • The demand for medical cyclotron with 16-18 MeV capacity is increasing as it offers maximum capacity and consistent yields.
  • General Electric Company; Varian Medical Systems, Inc; IBA; Sumitomo Heavy Industries, Ltd; Siemens AG; Advanced Cyclotron Systems; isoSolution Inc; ALCEN; Ionetix Corporation, and Best Cyclotron Systems, Inc. are among the leading companies operating in the medical cyclotron market.

Global Medical Cyclotron Market Forecast to 2027 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, March 12, 2021
Medical devices, Health, Particle accelerators, Accelerator physics, Cyclotron, Nuclear medicine, MEV, Physics, Physical sciences, Academic disciplines

The "Medical Cyclotron Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, Capacity, End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Cyclotron Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, Capacity, End User, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • According to this report the global medical cyclotron market is expected to reach US$ 238.21 million by 2027 from US$ 180.00 million in 2019.
  • Based on capacity, the medical cyclotron market is segmented into 10-12 MeV, 16-18 MeV, 19-24 MeV, and 24 MeV and above.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Cyclotron launches unified security administration and governance - TeamsHub by Cyclotron Secure

Retrieved on: 
Thursday, February 18, 2021
Computing, Technology, Computer companies, Accelerator physics, Particle accelerators, Cyclotron, Nuclear medicine, Cloud computing, Microsoft, Computer security

Due to the changing work patterns with more remote or flex workers, online security has become even more important.

Key Points: 
  • Due to the changing work patterns with more remote or flex workers, online security has become even more important.
  • It has been the DNA of our product with each and every release of TeamsHub by Cyclotron," added Logu Krishnan, Director of Technology.
  • "TeamsHub by Cyclotron Secure is the ultimate security experience for the entire organization.
  • TeamsHub by Cyclotron is a unified platform that caters to automated governance, administration and security of Microsoft Cloud.

Health Canada Approves Cyclotron Produced Technetium-99m utilizing the ARTMS QIS™ and Solid Targets

Retrieved on: 
Tuesday, December 22, 2020
Science, Cardiology, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Physical sciences, Natural sciences, Radiopharmaceuticals, Chemistry, Medical physics, Medicinal radiochemistry, Radiochemistry, Technetium-99m, TRIUMF, Particle accelerators, Technetium, Cyclotron

ARTMS Inc. (ARTMS) is excited to announce Health Canadas marketing approval of cyclotron produced technetium-99m (99mTc) for clinical use.

Key Points: 
  • ARTMS Inc. (ARTMS) is excited to announce Health Canadas marketing approval of cyclotron produced technetium-99m (99mTc) for clinical use.
  • For the Health Canada submission, ARTMS provided technical expertise and the solid targets required for production to a Canadian consortium consisting of BC Cancer, TRIUMF, Lawson Health Research and the Centre for Probe Development and Commercialization.
  • The team at ARTMS is proud to have played a key role in the development and eventual approval of cyclotron produced 99mTc by Health Canada.
  • ARTMS has a variety of solid targets commercially available with optimal production yields resulting when the targets are used in combination with ARTMS QUANTM Irradiation System (QISTM).

The Medical Cyclotron Market 2020-2024 - Featuring ALCEN, Ebco Industries Ltd., General Electric Co., Among Others | Technavio

Retrieved on: 
Tuesday, November 17, 2020
Radiology, Health, Medical devices, Accelerator physics, Particle accelerators, Cyclotron, Market analysis, Nuclear medicine, Physical sciences, Physics, Applied sciences

The medical cyclotron market is poised to grow by USD 55.98 mn during 2020-2024 progressing at a CAGR of almost 6% during the forecast period.

Key Points: 
  • The medical cyclotron market is poised to grow by USD 55.98 mn during 2020-2024 progressing at a CAGR of almost 6% during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20201117005915/en/
    Technavio has announced its latest market research report titled Global Medical Cyclotron Market 2020-2024 (Graphic: Business Wire)
    The report on the medical cyclotron market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The medical cyclotron market analysis includes product segment and geography landscape.
  • This study identifies the use of medical cyclotron technology in nuclear medicine as one of the prime reasons driving the medical cyclotron market growth during the next few years.